<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20100707171835+02'00'</creation_date><modification_date>D:20100707171838+02'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-06-353_h_w_dec_13.pdf</pdf_file></head><body><section><header>en  
   en</header></section><section><header>en</header></section><section><header>en  
   en</header><p>european commission brussels, 5.7.2010 c(2010)4781</p></section><section><header>commission decision of 5.7.2010 
 amending the marketing authorisation for &quot;thelin - sitaxentan sodium&quot;, a 
 medicinal product for human use, granted by decision c(2006)3721</header><p>(only the english text is authentic)</p></section><section><header>en</header><p>2</p></section><section><header>en</header></section><section><header>commission decision of 5.7.2010 
 amending the marketing authorisation for &quot;thelin - sitaxentan sodium&quot;, a 
 medicinal product for human use, granted by decision c(2006)3721 
 (text with eea relevance)</header><p>the european commission, having regard to the treaty on the functioning of the european union, 
 having regard to regulation (ec) no 726/2004 of the european parliament and of the 
 council of 31 march 2004 laying down community procedures for the authorisation and 
 supervision of medicinal products for human and veterinary use and establishing a 
 european medicines agency
 1, having regard to commission regulation (ec) no 1085/2003 of 3 june 2003 concerning 
 the examination of variations to the terms of a marketing authorisation for medicinal 
 products for human use and veterinary medicinal products falling within the scope of 
 council regulation (eec) no 2309/93
 2, and in particular the first subparagraph of article 6(10) thereof, 
 having regard to the application submitted by encysive (uk) limited on 20 december 
 2009 under article 6(1) of commission regulation (ec) no 1085/2003, 
 having regard to directive 2001/83/ec of the european parliament and of the council of 
 6 november 2001 on the community code relating to medicinal products for human use
 3, and in particular article 61(3) thereof, 
 having regard to the opinion(s) of the european medicines agency, formulated by the 
 committee for medicinal products for human use on 22 april 2010, 
 whereas: 
 (1)</p><p>an examination of the major variation(s) type ii to the terms of the marketing 
 authorisation for the medicinal product &quot;thelin - sitaxentan sodium&quot;, which is 
 entered in the community register of medicinal products under number(s) 
 eu/1/06/353/001-005 and the placing on the market of which was authorised by 
 decision c(2006)3721 of 10 august 2006, has shown that the product remains in 
 compliance with the requirements set out in directive 2001/83/ec of the 
 european parliament and of the council of 6 november 2001 on the community 
 code relating to medicinal products for human use
 4.</p><p>
 1 oj l 136, 30.4.2004, p. 1. 2 oj l 159, 27.6.2003, p. 24. 3 oj l 311, 28.11.2001, p. 67. 4 oj l 311, 28.11.2001, p. 67.</p></section><section><header>en</header><p>3</p></section><section><header>en</header><p>(2) the marketing authorisation should be subject to compliance with revised 
 conditions, set out in annex ii to this decision. the implementation of certain of 
 these conditions with regard to the safe and effective use of the medicinal product 
 is to be ensured by the member states, in accordance with article 127a of 
 directive 2001/83/ec. to this effect, commission decision (2010)4782 of 
 5.7.2010 is simultaneously being addressed to the member states. 
 (3)</p><p>it is therefore appropriate to accept the application(s) in respect of (a) major 
 variation(s) to the terms of the marketing authorisation and to amend decision 
 c(2006)3721 accordingly. 
 (4)</p><p>encysive (uk) limited submitted, under article 61(3) of directive 2001/83/ec, a 
 notification(s) for changes to an aspect of the labelling or the package leaflet, 
 which has (have) not yet been included in decision c(2006)3721 of 10 august 
 2006. 
 (5)</p><p>the marketing authorisation should be updated, and decision c(2006)3721 
 amended accordingly. 
 (6)</p><p>for the sake of clarity and transparency, it is advisable, following the amendment 
 of part or parts of the annexes, to provide for a consolidated version thereof. the 
 annexes to decision c(2006)3721 should therefore be replaced, 
 has adopted this decision: 
 article 1 decision c(2006)3721 is amended as follows: 1) the following list of notifications for changes to an aspect of the labelling or the 
 package leaflet is added to the updated marketing authorisation; 
 application number 
 annex (eu numbers affected) 
 emea/h/c/679/n/30 
 iiib (eu/1/06/353/001-005)</p><p>
 2) annex i is replaced by the text set out in annex i to this decision; 
 3) annex ii is replaced by the text set out in annex ii to this decision; 
 4) annex iii b is replaced by the text set out in annex iii b to this decision.</p></section><section><header>en</header><p>4</p></section><section><header>en</header><p>article 2 this decision is addressed to encysive (uk) limited, alder castle house, 10 noble street, london ec2v 7qj, united kingdom. 
 done at brussels, 5.7.2010.</p><p>for the commission</p><p>
 paola testori coggi</p><p>
 director-general</p></section></body></xml>